Business Medical Dialogues
    • facebook
    • twitter
    Sign in Signup
    • facebook
    • twitter
    Sign in Signup
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    Sign InRegister
    Business Medical Dialogues
    Sign inRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Roche stock up 12...

    Roche stock up 12 billion dollars on cancer, hemophilia trials; rivals hit

    By Ruby Khatun KhatunPublished On 2017-11-22T10:00:10+05:30  |  Updated On 2021-08-18T12:14:37+05:30

    ZURICH: Roche shares were lifted on Monday by two trial wins for its new cancer and hemophilia drugs, potential blockbusters that the Swiss drugmaker is counting on to offset shrinking revenue from older medicines.


    Along with Roche's multiple sclerosis medicine Ocrevus, the drugs are pillars of Chief Executive Severin Schwan's plan to offset the patent expiry of top-sellers Rituxan, Avastin, and Herceptin which account for $20 billion in annual sales.


    Roche said Tecentriq had cut the risk of lung cancer worsening when mixed with other treatments, while hemophilia agent Hemlibra had reduced bleeds in a new group of patients. This weighed on other pharmaceutical stocks - The Shire, a rival in the hemophilia market, fell 3 percent, while Merck & Co and Bristol-Myers Squibb, key competitors in cancer, fell 2.5 and 1.3 percent respectively.


    Roche's shares were up 6.5 percent at 1555 GMT, adding more than $12 billion to the company's market capitalization.



    Analysts said the trial results put Roche's defense strategy on the firmer ground.

    "We view these results as likely sufficient to begin turning the tide of biosimilar pessimism," Barclays analyst Emmanuel Papadakis, who has an "overweight" rating on the shares, said.



    Biosimilars -- biological drugs with the same effectiveness as the older name-brand medicines they mimic -- are quickly winning approval and denting Roche's revenue. Samsung Bioepis on Sunday won approval for a Herceptin copy in Europe.

    CANCER COCKTAIL


    With lung cancer easily the largest oncology market, Roche's trial of Tecentriq, Avastin and chemotherapy has been closely watched as it seeks to catch rivals in cancer immunotherapy.


    The mixture "provided a statistically significant and clinically meaningful reduction" in the risk of disease worsening or death compared to Avastin plus chemotherapy in first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC), Roche said.


    Initial observations on improving overall survival were "encouraging" and will be reported in the first half of 2018, it added.


    "We are extremely encouraged by these results and will submit these data to health authorities globally with the goal of bringing a potential new standard of care for the initial treatment of lung cancer," Sandra Horning, Roche's chief medical officer, said.


    So far, Tecentriq's sales - expected at around $500 million this year - pale compared to Keytruda from Merck and Opdivo from Bristol-Myers.


    Keytruda, which has an edge in lung cancer after U.S. approval as a first-line treatment, should hit $3.7 billion in sales this year, analysts estimate, while Opdivo revenue is on track to rise nearly four-fold to $4.8 billion.


    Monday's readout from Roche, while giving only bare details, may help the Basel-based drugmaker make up ground since results from Merck's and BMS's own combination lung cancer trials are still some way off.


    Meanwhile, AstraZeneca's immuno-oncology drug cocktail against lung cancer failed earlier this year, raising concerns about the approach as chemotherapy combinations like Roche's rack up trial wins.


    Hemlibra's latest trial result comes after the $482,000-per-year medicine was approved last week in the United States for patients who have developed resistance to clotting factors.


    In Monday's readout, Roche's drug reduced the risk of treated bleeds in patients without resistance.


    Peak sales of Hemlibra, estimated by some analysts at more than $4 billion, will hinge on getting approval for all hemophilia patients.


    "Hemlibra is poised to become a major product in the hemophilia A market ... while Tecentriq could now become an important first-line option in non-small-cell lung carcinoma," said Berenberg analyst Alistair Campbell.











    (Reporting by John Miller; Additional reporting by Ben Hirschler in London; Editing by Michael Shields and Andrew Heavens)








    Avastin Bristol-Myers Squibb cancer drugs Hemlibra hemophilia Herceptin lung cancer Merck multiple sclerosis Ocrevus pharma news Rituxan Roche Severin Schwan Shares Tecentriq trials 
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Pharmaceuticals safe in PET packaging: High-level committee

      Pharmaceuticals safe in PET packaging: High-level committee

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 29 March 2022 11:15 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X